Antidepressant selection and economic outcome: a review of methods and studies from clinical practice.
BACKGROUND
Economic considerations increasingly play a role in the selection of antidepressant drugs and are often based on analyses from prospective and retrospective studies. However, the non-randomisation found in retrospective studies may result in significant selection bias.


OBJECTIVE
To highlight the use of statistical methods in non-randomised studies and the application of those methods to economic analyses.


METHODS
The literature on the observational studies of economic outcomes with alternative antidepressants is reviewed and several statistical methodologies to control for biases that can occur in non-randomised study designs are described.


RESULTS
In comparisons of antidepressant drugs, differences in acquisition costs are consistently found to be at least offset by other components of care when broad measures of health care resource utilisation are considered.


CONCLUSIONS
Economic evaluations of antidepressants should be based on broad measures of health care expenditure and can rely on data generated in real-world settings if appropriate statistical methods are used to control for the potential biases of non-randomisation.
Crown
W H
WH
The MEDSTAT Group, 125 Cambridge Park Drive, Cambridge, MA 02140, USA. Bill_Crown@MEDSTAT.com
D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D015983:Selection Bias; D016896:Treatment Outcome
D000928:Antidepressive Agents